SCHEMBL3564007

SCHEMBL3564007

Cc1ccccc1C(NC(=O)Nc1ccc(Cl)cc1)C(=O)Nc1ccc(N(C)c2ccncc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
RAB9A P51151 5/20 0.42
NPC1 O15118 3/20 0.42
RAF1 P04049 1/20 0.41
FFAR2 O15552 1/20 0.40
CNR1 P21554 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NAMPT P43490 1/20 0.39
UTS2R Q9UKP6 2/20 0.39
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5813908 0.84 CNR1 (0.53) KMT2AMEN1RAB9ANPC1CNR1
SCHEMBL3564003 0.80 FFAR2 (0.39) KMT2AMEN1RAB9ANPC1RAF1
SCHEMBL8262955 0.80 F10 (0.45) KMT2AMEN1RAB9ANPC1CNR1
SCHEMBL3557437 0.77 CNR1 (0.52) KMT2AMEN1RAB9ANPC1CNR1
SCHEMBL3559107 0.76 F10 (0.46) KMT2AMEN1RAB9ANPC1CNR1
SCHEMBL3557262 0.75 CNR1 (0.50) KMT2AMEN1RAB9ACNR1SMN1; SMN2
SCHEMBL3568353 0.75 F10 (0.44) RAB9ANPC1CNR1UTS2RMAPT
SCHEMBL3566269 0.75 MEN1 (0.46) KMT2AMEN1RAB9ANPC1CNR1
SCHEMBL3559218 0.74 ALDH1A1 (0.54) RAB9ANPC1CNR1SMN1; SMN2POLB
SCHEMBL3562246 0.73 CNR1 (0.40) KMT2AMEN1RAB9ANPC1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 KMT2A 4014/4885MEN1 2311/4885RAB9A 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.